» Articles » PMID: 38637601

Impact of Insertion into the Left Internal Jugular Vein in Chemoport-associated Infections: a Retrospective Single-center Study of 1690 Cases

Overview
Journal Sci Rep
Specialty Science
Date 2024 Apr 18
PMID 38637601
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed chemoport insertion procedures to evaluate infectious morbidity and factors causing infection. This single-center retrospective study included 1690 cases of chemoport implantation between January 2017 and December 2020. Overall, chemoports were inserted in 1582 patients. The average duration of chemoport use was 481 days (range 1-1794, median 309). Infections occurred in 80 cases (4.7%), with 0.098 per 1000 catheter-days. Among the 80 cases in which chemoports were removed because of suspected infection, bacteria were identified in 48 (60%). Significantly more cases of left internal jugular vein punctures were noted in the infected group (15 [18.8%] vs. 147 [9.1%]; p = 0.004). Pulmonary embolism was significantly different between the infection groups (3 [3.8%] vs. 19 (1.2%), p = 0.048). The hazard ratio was 2.259 (95% confidence interval [CI] 1.288-3.962) for the left internal jugular vein, 3.393 (95% CI 1.069-10.765) for pulmonary embolism, and 0.488 (95% CI 0.244-0.977) for chronic obstructive pulmonary disease. Using the right internal jugular vein rather than the left internal jugular vein when performing chemoport insertion might reduce subsequent infections.

References
1.
Fischer L, Knebel P, Schroder S, Bruckner T, Diener M, Hennes R . Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients. Ann Surg Oncol. 2008; 15(4):1124-9. DOI: 10.1245/s10434-007-9783-z. View

2.
Jahangiri F, Salek M, Nassiri S, Samadi F, Koohian Mohammadabadi M . Results of Port-A-Cath Implantation: A Cross-Sectional Study about a Single Tertiary Cancer Center Experience. Med J Islam Repub Iran. 2022; 36:64. PMC: 9448478. DOI: 10.47176/mjiri.36.64. View

3.
Chang L, Tsai J, Huang S, Shih C . Evaluation of infectious complications of the implantable venous access system in a general oncologic population. Am J Infect Control. 2003; 31(1):34-9. DOI: 10.1067/mic.2003.29. View

4.
Zaghal A, Khalife M, Mukherji D, El Majzoub N, Shamseddine A, Hoballah J . Update on totally implantable venous access devices. Surg Oncol. 2012; 21(3):207-15. DOI: 10.1016/j.suronc.2012.02.003. View

5.
Davies M, Feeley T, Moore D, Shanik G . Home parenteral nutrition using a totally implanted subcutaneous venous access device. Br J Clin Pract. 1990; 44(12):750. View